Preliminary results of proton beam therapy for esophageal carcinoma
Reporter John P. Plastaras, MD, PhD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: October 13, 2006
Presenter: Jiamin Li, Suwen Liu, Jianguang Zhang Affiliation: Wanjie Proton Therapy Center, Zibo Wanjie Hospital, Boshan, Zibo, Shandong Province, China
Esophageal cancer has historically been treated with a combination of surgery (when possible), photon radiotherapy, and chemotherapy
Radiation therapy doses to the esophagus are limited by nearby critical structures including the spinal cord, lungs, and heart, which can lead to acute and chronic toxicities.
Dose escalation in definitive radiation treatment of esophageal cancer is somewhat controversial, as the RTOG trial had excessive deaths on the high dose treatment arm (although several of these deaths were in patients that did not receive the full radiation dose). Currently used radiation doses are associated with poor local control.
Proton radiotherapy offers a way to increase the total tumor dose (and hopefully local control) without excessive toxicity for definitive radiation treatment of esophagus cancer
The feasibility of proton beam therapy for esophageal carcinoma was evaluated
Material and Methods
4 patients with esophageal carcinoma (age 50-82) were treated at the Wanjie Proton Therapy Center between 12/2004 and 1/2006
Tumor length was determined by barium swallow, esophagoscopy, and PET-CT
Pathology: 3 SCC and 1 adenocarcinoma
1: middle third, 8 cm, regional mediastinal LN
2: lower third, 5 cm, no regional LN
3: upper third, 4 cm
4: 82 yo with abdominal esophageal cancer, multiple gastric LN
2 patients were treated with a combination of photons and protons, 2 were treated with protons only
Fields: 2 fields, AP-PA were used. 3-4 cm beyond primary tumor cephalad and caudad lateral borders were 1-1.5 cm
Fractionation/Dose: 1.8 or 2.0 Gy for photon and proton, total dose 60 to 66 Gy
Some sample DVH curves were presented, with excellent coverage of target volumes with relatively low dose to lung and spinal cord. Comparison with conventional photon plans was not presented.
All patients completed treatment without interruption
No esophageal ulcers were seen with 12 month follow up
Grade 1 in 3 patients
Grade 2 in 1 patient
3 of 4 had a complete response within 3 months
Patient 4 died of distant metastases 13 months later
Patient 3 relapsed 12 months later
Patients 1 and 2 are free of disease after >1 yr follow-up
Proton beam radiation therapy was feasible, well-tolerated and effective for patient with esophageal cancer
Proton beam therapy can spare more surrounding tissues such as lung, heart, and spinal cord
Local control rates are comparable to those treated with conventional radiation therapy
Acute toxicity is lower that that for conventional therapy, but more follow-up is needed for late effects
Clinical and Scientific Implications
As proton therapy becomes more widespread, different malignancies will be treated with protons. Good dosimetry with AP-PA protons fields was demonstrated in this study, but a comparison with photon plans would have made this study more compelling.
1 of 4 patients had a local relapse, but the dose was not specified for this patient
The use of concurrent chemotherapy was not specified in this study. The acute toxicities would likely be worse with concurrent chemotherapy.
Dose escalation for definitive radiotherapy of the esophagus may be attempted with proton therapy, given the ability to spare normal structures.
The use of proton therapy in the pre- or post-operative setting remains to be explored.
Apr 24, 2014 - Long-term survival may be increased in medium-risk prostate cancer patients who receive short-term androgen deprivation therapy before and during radiation treatment compared with men who receive radiation alone. In addition, proton beam therapy may be associated with a decreased risk of disease recurrence after 10 years and has minimal side effects after one year, according to research presented at the 51st Annual Meeting of the American Society for Radiation Oncology, held from Nov. 1 to 5 in Chicago.